



Aravax forms research collaboration with Benaroya Research Institute

20th January 2017– Today Aravax established a collaboration with the prestigious Benaroya Research Institute in Seattle. The research group led by Erik Wambre (PhD) will work with Aravax on research into immunological responses to Aravax's therapy, PVX108.

PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic reactions to peanuts. Unlike other peanut allergy immunotherapies under development, the peptides do not contain the parts of the peanut proteins that cause life-threatening anaphylactic reactions. Understanding the mechanisms by which the immune system induces and controls allergic inflammation is critical to monitor and understand changes induced from therapeutics, such as PVX108. The collaboration with the Benaroya Research Institute will enable further validation and a better understanding of the immunological actions and effects of PVX108 and will help inform future clinical development. Aravax plans to test this therapeutic in clinical trials in 2018.

Ends

Media enquiries:

Aravax & MRCF: Andrew Hamilton +61420 447 669 or ah@manacommunications.com

About Aravax

Aravax is a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The treatment will use highly targeted technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment.

Aravax's technology is underpinned by over a decade of research led by Professor Robyn O'Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council.

The novel technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. These fragments do not contain the parts of the nut proteins that cause the life-threatening anaphylactic reactions that can make other proposed peanut allergy therapeutics unsafe.

Aravax Pty Ltd

Level 9, 31 Queen Street, Melbourne VIC 3000 Australia

Office +61 3 9657 0700 | Fax +61 3 9657 0777



Aravax is headquartered in Melbourne, Australia.

For more information visit: www.aravax.com.au

About the Australian Medical Research Commercialisation Fund (MRCF)

The MRCF collaboration is managed by the venture capital firm Brandon Capital Partners, and provides seed and venture capital investment to support the development and growth of Australian life science companies.

Established in late 2007, the MRCF is a unique collaboration between major Australian superannuation funds, over 50 leading medical research institutes and research hospitals in Australia and New Zealand. The MRCF supports the development and commercialisation of very early-stage biomedical discoveries originating from these member research organisations, providing both capital and expertise to guide the successful development of new therapies. The MRCF acknowledges the support of the Australian and New Zealand governments, as well as the state governments of Victoria, New South Wales, Western Australia, Queensland, South Australia and the Australian Capital Territory.

For more information visit: www.mrcf.com.au

Aravax Pty Ltd

Level 9, 31 Queen Street, Melbourne VIC 3000 Australia

Office +61 3 9657 0700 | Fax +61 3 9657 0777